Calcitonin Gene-Related Peptide Antagonist Use and Atypical Femur Fractures: A Case Report.

CASE: A 56-year-old woman presented with bilateral hip pain status postmechanical fall. Imaging confirmed bilateral AFFs with lateral cortical beaking. The patient was found to be on a calcitonin gene-related peptide (CGRP) antagonist, Erenumab, for treatment of recurrent migraines. CGRP is a neuropeptide and vasodilator produced by neurons in both the central and peripheral nervous system. She was treated with bilateral femoral intramedullary nails, followed by postoperative rehabilitation with physical therapy and outpatient follow-up visits.

CONCLUSION

Erenumab is a CGRP antagonist, which increases bone formation, and may be associated with atypical femur fractures. Further investigations are warranted.